Selected research
Market Structure
Global Recombinant Zoster Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Recombinant Zoster Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Recombinant Zoster Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Recombinant Zoster Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Recombinant Zoster Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Recombinant Zoster Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Recombinant Zoster Vaccine include GSK, Merck and Changchun Bcht Biotechnology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Recombinant Zoster Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Recombinant Zoster Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Recombinant Zoster Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Zoster Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
Recombinant Zoster Vaccine Segment by Company
GSK
Merck
Changchun Bcht Biotechnology
Recombinant Zoster Vaccine Segment by Type
Monovalent Vaccine
Combination Vaccine
Recombinant Zoster Vaccine Segment by Application
Above 50 Years Old
Below 50 Years Old
Recombinant Zoster Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Zoster Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Zoster Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Zoster Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Recombinant Zoster Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant Zoster Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Recombinant Zoster Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Recombinant Zoster Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Monovalent Vaccine
- Combination Vaccine
Applications
- Above 50 Years Old
- Below 50 Years Old
Companies covered
- GSK
- Merck
- Changchun Bcht Biotechnology
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Recombinant Zoster Vaccine Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Recombinant Zoster Vaccine Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Recombinant Zoster Vaccine Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Recombinant Zoster Vaccine Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Recombinant Zoster Vaccine Market Dynamics
- 2.1 Recombinant Zoster Vaccine Industry Trends
- 2.2 Recombinant Zoster Vaccine Industry Drivers
- 2.3 Recombinant Zoster Vaccine Industry Opportunities and Challenges
- 2.4 Recombinant Zoster Vaccine Industry Restraints
3 Recombinant Zoster Vaccine Market by Manufacturers
- 3.1 Global Recombinant Zoster Vaccine Revenue by Manufacturers (2021-2026)
- 3.2 Global Recombinant Zoster Vaccine Sales by Manufacturers (2021-2026)
- 3.3 Global Recombinant Zoster Vaccine Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Recombinant Zoster Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Recombinant Zoster Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Recombinant Zoster Vaccine Manufacturers, Product Type & Application
- 3.7 Global Recombinant Zoster Vaccine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Recombinant Zoster Vaccine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Recombinant Zoster Vaccine Players Market Share by Revenue in 2025
- 3.8.3 2025 Recombinant Zoster Vaccine Tier 1, Tier 2, and Tier 3
4 Recombinant Zoster Vaccine Market by Type
- 4.1 Recombinant Zoster Vaccine Type Introduction
- 4.1.1 Monovalent Vaccine
- 4.1.2 Combination Vaccine
- 4.2 Global Recombinant Zoster Vaccine Sales by Type
- 4.2.1 Global Recombinant Zoster Vaccine Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Recombinant Zoster Vaccine Sales by Type (2021-2032)
- 4.2.3 Global Recombinant Zoster Vaccine Sales Market Share by Type (2021-2032)
- 4.3 Global Recombinant Zoster Vaccine Revenue by Type
- 4.3.1 Global Recombinant Zoster Vaccine Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Recombinant Zoster Vaccine Revenue by Type (2021-2032)
- 4.3.3 Global Recombinant Zoster Vaccine Revenue Market Share by Type (2021-2032)
5 Recombinant Zoster Vaccine Market by Application
- 5.1 Recombinant Zoster Vaccine Application Introduction
- 5.1.1 Above 50 Years Old
- 5.1.2 Below 50 Years Old
- 5.2 Global Recombinant Zoster Vaccine Sales by Application
- 5.2.1 Global Recombinant Zoster Vaccine Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Recombinant Zoster Vaccine Sales by Application (2021-2032)
- 5.2.3 Global Recombinant Zoster Vaccine Sales Market Share by Application (2021-2032)
- 5.3 Global Recombinant Zoster Vaccine Revenue by Application
- 5.3.1 Global Recombinant Zoster Vaccine Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Recombinant Zoster Vaccine Revenue by Application (2021-2032)
- 5.3.3 Global Recombinant Zoster Vaccine Revenue Market Share by Application (2021-2032)
6 Global Recombinant Zoster Vaccine Sales by Region
- 6.1 Global Recombinant Zoster Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Recombinant Zoster Vaccine Sales by Region (2021-2032)
- 6.2.1 Global Recombinant Zoster Vaccine Sales by Region (2021-2026)
- 6.2.2 Global Recombinant Zoster Vaccine Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Recombinant Zoster Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Recombinant Zoster Vaccine Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Recombinant Zoster Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Recombinant Zoster Vaccine Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Recombinant Zoster Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Recombinant Zoster Vaccine Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Recombinant Zoster Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Recombinant Zoster Vaccine Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Recombinant Zoster Vaccine Revenue by Region
- 7.1 Global Recombinant Zoster Vaccine Revenue by Region
- 7.1.1 Global Recombinant Zoster Vaccine Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Recombinant Zoster Vaccine Revenue by Region (2021-2026)
- 7.1.3 Global Recombinant Zoster Vaccine Revenue by Region (2027-2032)
- 7.1.4 Global Recombinant Zoster Vaccine Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Recombinant Zoster Vaccine Revenue (2021-2032)
- 7.2.2 North America Recombinant Zoster Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Recombinant Zoster Vaccine Revenue (2021-2032)
- 7.3.2 Europe Recombinant Zoster Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Recombinant Zoster Vaccine Revenue (2021-2032)
- 7.4.2 Asia-Pacific Recombinant Zoster Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Recombinant Zoster Vaccine Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Recombinant Zoster Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 GSK
- 8.1.1 GSK Company Information
- 8.1.2 GSK Business Overview
- 8.1.3 GSK Recombinant Zoster Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 GSK Recombinant Zoster Vaccine Product Portfolio
- 8.1.5 GSK Recent Developments
- 8.2 Merck
- 8.2.1 Merck Company Information
- 8.2.2 Merck Business Overview
- 8.2.3 Merck Recombinant Zoster Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Merck Recombinant Zoster Vaccine Product Portfolio
- 8.2.5 Merck Recent Developments
- 8.3 Changchun Bcht Biotechnology
- 8.3.1 Changchun Bcht Biotechnology Company Information
- 8.3.2 Changchun Bcht Biotechnology Business Overview
- 8.3.3 Changchun Bcht Biotechnology Recombinant Zoster Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Changchun Bcht Biotechnology Recombinant Zoster Vaccine Product Portfolio
- 8.3.5 Changchun Bcht Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Recombinant Zoster Vaccine Value Chain Analysis
- 9.1.1 Recombinant Zoster Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Recombinant Zoster Vaccine Production Mode & Process
- 9.2 Recombinant Zoster Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Recombinant Zoster Vaccine Distributors
- 9.2.3 Recombinant Zoster Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst